ClinicalTrials.gg
CompletedNCT05212168G1-1 ChallengeUpdated Nov 5, 2025Results posted

Norovirus Challenge Study

A Phase 1/2 interventional study of VXA-G1.1-NN and Placebo Tablets in Norovirus Infections, sponsored by Vaxart. Completed at 1 site in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-05.

Sponsored by Vaxart · Phase 1/2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Caliciviridae Infections with a site in United States — none open to participants now, none under way, none of them phase 3. Caliciviridae Infections · United States.

Enrollment
Largest of 11
165 · median 60
Started
2021
with 2 others
Phase 1/2
3 of 11
none open now
Registered
9th of 11
by date
Lead sponsor
7 of 11
Vaxart

Among the 11 studies in Caliciviridae Infections with a site in United States, this one has the largest enrollment, is one of 3 that started in 2021, is one of 3 in phase 1/2, and was the 9th registered.

Caliciviridae Infections

20 studies on the registry are indexed under Caliciviridae Infections; 2 are open to participants now.

Browse Caliciviridae Infections studies →

Open to participants now

None of the 11 studies in Caliciviridae Infections with a site in United States is open now. The open studies under Caliciviridae Infections, anywhere →

Who these studies take

Of the 2 Caliciviridae Infections studies recruiting now, none set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Caliciviridae Infections with a site in United States as a file.
02

Study summary

This is a Phase 2b randomized, double-blind, placebo-controlled vaccination and challenge study to assess the protective efficacy of the Vaxart Norovirus vaccine (VXA-G1.1-NN). Healthy adults will be randomized in a 1:1 ratio to receive one oral dose of vaccine or placebo.

  • Arm 1: VXA-G1.1-NN oral vaccine tablets [1x1011 IU±0.5 log]
  • Arm 2: Placebo tablets similar in appearance and number to active vaccine tablets

Approximately 28 days post-vaccination, subjects will be admitted to an isolation ward and challenged with the NV GI.1 Norwalk challenge strain. After challenge, subjects will be monitored for signs and symptoms of acute gastroenteritis (AGE) from Day 29 to discharge. At 4 days post challenge (Day 33) asymptomatic subjects will be discharged from the isolation ward and will be followed in a series of outpatient visits and telephone calls. Symptomatic subjects may be kept in the isolation ward for up to an additional 3 days.

Read the detailed description

Study Population Healthy male and female adult volunteers age 18 to 49 years inclusive with blood type O or A and who are confirmed H type-1 antigen secretory positive Investigational Product

Active Vaccine:

  • Norovirus GI.1 Norwalk VP1 Vaccine (VXA-G1.1-NN), an Oral E1/E3-Deleted Replication-Defective Recombinant Adenovirus serotype 5 with double-stranded ribonucleic acid (dsRNA) Adjuvant. The vaccine vector encodes for a full-length VP1 gene from Norwalk virus (NV). The adjuvant is a short hairpin RNA, expressed as a 21 nucleotide sequence (GAAACGA TATGGGCTGAATAC) as a tandem sequence in forward and reverse orientations separated by 6 nucleotides that comprise the loop of the RNA. The final drug product (DP) is formulated into enteric-coated tablet.
  • Dose: 1x10E11 IU±0.5 log

Placebo Control:

  • Oral tablets similar in appearance and number to active vaccine tablets Multiple tablets of study drug will be dispensed to allow delivery of the intended vaccine dose (1x10E11 IU). A matching number of placebo tablets will be dispensed to maintain the study blinding.

Viral Challenge Inoculum

  • Norovirus GI.1 (Norwalk Virus Inoculum Lot 001-09NV, IND 14697)
  • Dose: 1x10E6 Genomic Copies (GC). A dose which allows 50% - 65% infectivity in the healthy adult population (per NV infection rate observed in the GI.1 viral titration study

Study Hypothesis Norovirus vaccine (VXA-G1.1-NN) will protect against Norovirus Gastroenteritis (NVG) related to norovirus (NoV) infection in the challenge model

Approximately 120 subjects will be dosed in the vaccination phase to ensure at least 100 subjects (\~ 50 VXA-G1.1-NN vaccine and 50 placebo) are available to participate in the challenge phase. Approximately 28 days post-vaccination, subjects will be admitted to an isolation ward and challenged with the NV GI.1 Norwalk challenge strain. After challenge, subjects will be monitored for signs and symptoms of acute gastroenteritis (AGE) from Day 29 to discharge. NV illness lasts 2-4 days and is self-limited. At 4 days post challenge (Day 33) asymptomatic subjects will be discharged from the isolation ward and will be followed in a series of outpatient visits and telephone calls. Symptomatic subjects may be kept in the isolation ward for up to an additional 3 days.

The following study visits and remote contacts will be conducted during the study

Vaccination Phase:

  • Pre-Screening Period (Days -90 to Screening) may be utilized for purposes of ascertaining subjects' H type-1 antigen secretory status and blood type
  • Screening Period (Days -45 to -1)
  • Day 1 Visit (Baseline assessments; day of randomization and vaccination)
  • Day 8 Visit (safety and evaluation of immune response)
  • Day 28 (evaluation of immune response; 1 day prior to challenge, start inpatient stay)

Challenge Phase:

  • Day 29 (viral challenge, sequestration)
  • Days 30 to 33 (sequestration - discharge; +3 days)
  • Day 36 Visit (evaluation of immune response and safety assessment)
  • Day 57 Visit (end of active period)

Safety Follow-Up:

  • Day 120, Day 180, Day 240 and Day 300 (follow-up contact)
  • Day 185 (follow-up phone call): Study completion

An independent Safety Monitoring Committee (SMC) will convene at pre-defined intervals during the norovirus challenge period, and also ad hoc as needed during the vaccination and challenge periods, to oversee the safety of the study.

03

Conditions studied

  • Norovirus Infections
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  1. Male or female between the ages of 18 - 49 years, inclusive
  2. Able to give written
  3. Healthy, as determined by the principal investigator (PI) or PI in consultation with the research monitor and Sponsor Healthy = No health concerns or medical illness, as determined by medical history, physical examination, vital signs, (ECG), and clinical laboratories (complete blood count (CBC), chemistry and urinalysis)
  4. Comprehension of the study requirements with ability and willingness to complete all assessments and comply with confinement period post viral challenge, and all scheduled visits and contacts
  5. Confirmed blood type (A or O)
  6. Demonstrated to be H type-1 antigen secretor positive (by saliva test)
  7. between 17 and 35 kg/m2, inclusive, at Screening
  8. Female participants must have a negative pregnancy test at pre-vaccination and pre-challenge and fulfill one of the following Criteria:

    1. At least one year ;
    2. Surgically sterile;
    3. Use of oral, implantable, transdermal or injectable for 30 days prior to immunization and until 60 days after challenge;

    i. A reliable form of contraception must be approved by the Investigator (eg, double barrier method, Depo-Provera, intrauterine device, Norplant, oral contraceptives, contraceptive patches) d. Not be sexually active (abstinent) or in a same sex relationship (must be discussed with site staff and documented)

  9. Male subjects must agree not to father a child or donate sperm, as well as to use contraception/barrier (a male condom) or be abstinent from heterosexual intercourse, from vaccination through the active period (Day 57)

Exclusion Criteria:

  1. Administration/use of any drug or device 30 days prior to vaccination through the active period (Day 57)
  2. Administration of any licensed vaccine within 30 days prior to vaccination or planned use of the above stated during the active period (through Day 57)
  3. Presence of a significant medical condition, which, in the opinion of the investigator, precludes participation in the study. Significant medical condition = for example, psychiatric conditions, or gastrointestinal disease, such as peptic ulcer, symptoms or evidence of active gastritis or gastroesophageal reflux disease, inflammatory bowel disease, alcohol or illicit drug abuse/dependency, or other laboratory abnormalities
  4. Laboratory values outside the range of normal for counts and the following coagulation tests: prothromibin time test (), activated partial thromboplastine time test (aPTT) and fibrinogen
  5. Any of the following history or conditions that may lead to higher risk of clotting events and/or thrombocytopenia:

    1. Family or personal history of bleeding or thrombosis
    2. History of heparin-related thrombotic events, and/or receiving heparin treatments
    3. History of or inflammatory disease
    4. Presence of any of the following conditions known to increase risk of thrombosis within 6 months prior to screening:

      • Recent surgery other than removal/ of cutaneous lesions
      • Immobility (confined to bed or wheelchair for 3 or more successive days)
      • Head trauma with loss of consciousness or documented brain injury
      • Receipt of anticoagulants for prophylaxis of thrombosis
      • Recent clinically significant infection
  6. Any one of the following ECG findings within 45 days prior to vaccination:

    Exclusionary ECG findings:

    1. F (interval duration > 450 msec (male) or > 470 msec (female)
    2. QRS interval greater than 120 msec
    3. PR interval greater than 220 msec
    4. Clinically significant ST-T wave changes or pathologic Q waves
  7. History of cancer or cancer treatment within past 3 years (excluding basal cell or squamous cell carcinomas)
  8. Presence of or medical condition possibly associated with impaired immune responsiveness, including diabetes mellitus or angioedema
  9. Donation or use of blood or blood products within 30 days prior to vaccination through the active period (Day 57)
  10. Diagnosed bleeding disorder or significant bruising or bleeding difficulties that could make blood draws problematic
  11. Any condition that resulted in the absence or removal of the spleen
  12. Evidence of confirmed infection with (HIV), surface antigen (HBsAg) or virus (HCV) with confirmatory assays
  13. Abnormal stool pattern (fewer than 3 bowel movements per week or more than 3 per day)
  14. History of irritable bowel disease or inflammatory digestive or gastrointestinal condition that could affect the distribution / safety evaluation of an orally administered vaccine targeting the mucosa of the small intestine.

    Such conditions may include but are not limited to:

    1. Esophageal Motility Disorder
    2. Malabsorption (e.g. Celiac disease, gluten intolerance)
    3. Pancreaticobiliary disorders
    4. Irritable bowel syndrome
    5. Inflammatory Bowel Disease
    6. Surgical Resection with the exception of appendectomy or a minor resection that is deemed acceptable by investigator and sponsor
    7. Gastroesophageal reflux disease (GERD)
    8. Hiatal Hernia
    9. Peptic Ulcer (History of cholecystectomy is not exclusionary)
  15. Use of proton pump inhibitors, H2 blockers or antacids within 7 days prior to vaccination through the active period (Day 57)
  16. Use of antibiotics within 30 days prior to vaccination through the active period (Day 57) Note: use of a brief (≤ 10 days) course of oral or topical antibiotic for minor upper respiratory infection (URI), urinary tract infection (UTI), dental work, or skin infection allowed within the screening period, but must be completed 7 days prior to first vaccination
  17. Use of medication known to affect the immune function (e.g. systemic and others) within 14 days prior to vaccination through the active period (Day 57)
  18. Regular use of nonsteroidal anti-inflammatory drugs within 7 days prior to vaccination through the active period (Day 57)
  19. Use of over-the-counter probiotics or antidiarrheals within 7 days prior to vaccination through the active period (Day 57)
  20. Evidence of recent (within 2 months of vaccination) or of current nonbacterial gastroenteritis suggestive of NV infection [vomiting or unformed or watery stools (> 2 during a 24-hour period)]
  21. Any gastroenteritis within the past 2 weeks prior to vaccination
  22. Acute disease within 72 hours prior to vaccination, defined as the presence of a moderate or severe illness with or without fever (as determined by the Investigator through medical history and physical examination). (Assessment may be repeated during screening period)
  23. Presence of a fever ≥ 38ºC measured orally at baseline
  24. History if hematochezia (blood in stool) or melena (black stool)
  25. Any significant hospitalization within the last year which in the opinion of the investigator or sponsor could interfere with study participation
  26. History of serious reactions to any vaccination such as anaphylaxis, respiratory problems, Guillain-Barre syndrome, hives or abdominal pain
  27. History of a or allergic reaction to any component of the investigational vaccine or placebo, including but not limited to fish gelatin. Subjects with known fish allergies should be excluded.
  28. History of drug, alcohol or chemical abuse within 1 year prior to vaccination
  29. Positive test for drugs of abuse or alcohol at screening, vaccination baseline and pre-challenge (except for previous marijuana use; concurrent or ongoing use of marijuana during the active study period).
  30. Consistent/habitual smoking within 2 months prior to vaccination (defined as smoking ≥ 1 pack of cigarettes a day). Smoking is not permitted during the inpatient stay
  31. Other conditions, in the clinical judgment of the investigator, that would jeopardize the safety or rights of a subject or interfere with the evaluation of the study

    Social/Occupational:

  32. Living with or having daily contact with children \< 5 years old or women known to be pregnant or nursing; this includes significant contact at home, school, day-care, or equivalent facilities
  33. Living with or having daily contact with elderly persons > 70 years of age or infirmed, diapered individuals, persons with disabilities or incontinence; this includes at work or visits to nursing homes and day-care or equivalent facilities
  34. Employment in the food service industry such as restaurant or cafeteria facilities; specifically, this includes persons whose employment requires food handling and processing in the 4 weeks following viral challenge
  35. Health-care workers with patient contact expected in the 4 weeks following viral challenge
  36. Expected contact, via employment or at home, with immunocompromised persons in the 4 weeks following viral challenge. Immunocompromised persons = HIV-positive, receiving immunosuppressive medications such as oral steroids, anti-neoplastic agents
  37. Presence of household members who have received the Ad4 or Ad7 vaccines within 2 months prior to vaccination
  38. Employment as an airline flight attendant or cruise ship crew, scheduled to work in the 4 weeks following challenge
  39. Persons planning to live in a confined environment (eg, a cruise, camp, etc.) in the 4 weeks following viral challenge
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Single group
Masking
Single (Participant)
Enrollment
165 participants (actual)

Study arms

  • Active comparator
    Active Vaccine Arm

    Subjects receiving Norovirus GI.1 Norwalk VP1 Vaccine, Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant

    Biological: VXA-G1.1-NN · Biological: Norovirus GI.1 Norwalk Virus Inoculum

  • Placebo comparator
    Placebo Arm

    Subject receiving Placebo oral tablets similar in appearance and number to active vaccine tablets

    Other: Placebo Tablets · Biological: Norovirus GI.1 Norwalk Virus Inoculum

Interventions

  • BiologicalVXA-G1.1-NN

    Norovirus GI.1 Norwalk VP1 Vaccine, Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant

  • OtherPlacebo Tablets

    Oral tablets similar in appearance and number to active vaccine tablets

  • BiologicalNorovirus GI.1 Norwalk Virus Inoculum

    Norwalk Virus Inoculum Lot 01-09NV

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced Norovirus Gastroenteritis (NVG)

    NVG is a composite endpoint defined as meeting both the definition of AGE and NV. AGE was defined as meeting any one of 3 criteria (diarrhea, vomiting, or diarrhea and vomiting) in any 24-hr rolling period. The individual criteria for diarrhea, vomiting, or diarrhea and vomiting were as follows: 1\. Diarrhea: i. ≥ 3 loose or liquid stools in any 24-hr rolling period, or ii. 400 g of loose or liquid stools in any 24-hr rolling period 2. Vomiting: ≥ 2 vomiting episodes in any 24-hr rolling period, or 3. Diarrhea and vomiting: i. one vomiting episode plus any loose or liquid stool in any 24-hr rolling period ii. one vomiting episode plus ≥ 2 of the following events in any 24-hr rolling period: 1. nausea 2. fever (oral temperature ≥ 37.6°C) 3. abdominal cramps or pains 4. abdominal gurgling or bloating 5. myalgia NV infection was defined as having 1 or more positive results in stool or urine by quantitative real time reverse transcription polymerase chain reaction (qRT-PCR).

    Time frame: Up to approximately Day 57

  2. Levels of Viral Protein 1, Major Capsid, or Surface Protein of Viruses (VP1)-Specific Immunoglobulin A (IgA) Antibody-Secreting Cell (ASC) Against Norwalk at Day 8

    Blood samples were collected at different timepoints throughout the study.

    Time frame: Day 8

  3. Geometric Mean Titer (GMT) of Histo-blood Group Antigen (HBGA) Blocking Antibodies Against NV by Blocking Titer 50 (BT50) at Day 28

    Blood samples were collected at different timepoints throughout the study. A positive change indicates an increase in titers.

    Time frame: Day 28

  4. VP1-specific Serum Immunoglobulin G (IgG) Response at Day 28

    Blood samples were collected at different timepoints throughout the study.

    Time frame: Day 28

  5. VP1-specific Serum IgA at Day 28

    Blood samples were collected at different timepoints throughout the study.

    Time frame: Day 28

Secondary outcomes

  1. Number of Participants Who Experienced Solicited Symptoms of Reactogenicity

    Solicited symptoms of reactogenicity included: * Gastrointestinal reactions: nausea, vomiting, diarrhea and abdominal pain * Systemic reactogenicity: malaise/fatigue, anorexia, fever, headache and myalgia

    Time frame: Up to Day 8

  2. Number of Participants Who Experienced Unsolicited Adverse Events (AEs) During the Vaccination Phase

    Unsolicited AEs referred to any AEs that occurred during a clinical trial but were not specifically pre-defined or actively sought by the study protocol. Unsolicited AEs could include any medical condition or symptom, whether or not it was related to the intervention being studied.

    Time frame: Up to Day 28 of Vaccination Phase (28-days phase)

  3. Number of Participants Who Experienced Serious AEs (SAEs), AEs of Specific Interest (AESIs), and New Onsets of Chronic Illness (NOCIs)

    A SAE was any AE that resulted in one or more of the following outcomes: death, a life-threatening event where the subject was at immediate risk of death (not hypothetically), inpatient hospitalization or the prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of normal life functions, congenital abnormality or birth defect, or an important medical event that, that jeopardized the participant's health or required medical or surgical intervention to prevent a serious outcome. A NOCI was defined as the diagnosis post-study drug administration of a new medical condition, which was chronic in nature, including those potentially controllable by medication (e.g., diabetes, asthma).

    Time frame: Up to approximately 12 months post vaccination

  4. Number of Participants Who Experienced Unsolicited AEs During the Challenge Phase

    Unsolicited AEs referred to any AEs that occurred during a clinical trial but were not specifically pre-defined or actively sought by the study protocol. Unsolicited AEs could include any medical condition or symptom, whether or not it was related to the intervention being studied.

    Time frame: Up to Day 29 of Challenge Phase (28-days phase)

  5. Number of Participants With AGE During the Inpatient Challenge Phase

    AGE was defined as meeting any one of 3 criteria (diarrhea, vomiting, or diarrhea and vomiting) in any 24-hr rolling period. The individual criteria for diarrhea, vomiting, or diarrhea and vomiting were as follows: 1\. Diarrhea: i. ≥ 3 loose or liquid stools produced in any 24-hr rolling period, or ii. 400 g of loose or liquid stools produced in any 24-hr rolling period 2. Vomiting: ≥ 2 vomiting episodes in any 24-hr rolling period, or 3. Diarrhea and vomiting: i. one vomiting episode plus any loose or liquid stool in any 24-hr rolling period ii. one vomiting episode plus ≥ 2 of the following events in any 24-hr rolling period: 1. nausea 2. fever (oral temperature ≥ 37.6°C) 3. abdominal cramps or pains 4. abdominal gurgling or bloating 5. myalgia

    Time frame: Day 28 of Challenge Phase (28-days phase)

  6. Severity of AGE Assessed Using the Modified Vesikari Scale

    The Modified Vesikari Scale is a tool used to assess the severity of AGE by evaluating symptoms such as diarrhea, vomiting, fever, and dehydration. It scores these symptoms based on their frequency and severity, with a minimum score of 0 and a maximum score of 20, where higher scores indicate more severe symptoms and lower scores suggest milder or no symptoms and severity.

    Time frame: Up to approximately Day 36

  7. Number of Participants Who Experienced Moderate or Severe Gastroenteritis

    Moderate or severe gastroenteritis was defined by cumulative loose stools ≥ 1000gr during the inpatient period.

    Time frame: Up to approximately Day 57

  8. Duration of AGE

    Time to onset of AGE was calculated as the time from challenge administration to the first recorded instance of an event satisfying the criteria for AGE. AGE was defined as meeting any of the 3 criteria: 1\. Diarrhea: i. ≥ 3 loose or liquid stools in any 24-hr rolling period, or ii. 400 g of loose or liquid stools in any 24-hr rolling period 2. Vomiting: ≥ 2 vomiting episodes in any 24-hr rolling period, or 3. Diarrhea and vomiting: i. one vomiting episode plus any loose or liquid stool in any 24-hr rolling period ii. one vomiting episode plus ≥ 2 of the following events in any 24-hr rolling period: 1. nausea 2. fever (oral temperature ≥ 37.6°C) 3. abdominal cramps or pains 4. abdominal gurgling or bloating 5. myalgia

    Time frame: Up to approximately Day 57

  9. Number of Participants Who Experienced Incidences of Diarrhea or Emesis

    Classification of diarrhea was done through grading stools with Grade 3 (thick liquid stool) to Grade 5 (clear water diarrheal stool) being considered diarrhea.

    Time frame: Up to approximately Day 57

  10. Number of Participants With Norovirus (NoV) Infection up to Challenge Period Day 8

    NoV infection was defined as a positive qRT-PCR in stool or emesis up to Challenge Period Day 8, and the presence of NV antigen in stool.

    Time frame: Challenge Phase Day 8 (equal to Study Day 36)

  11. Geometric Mean Genome Copies (GCs) of NoV Shedding in Stool Measured by qRT-PCR

    NoV shedding was assessed by qRT-PCR. Stool samples were reported on 10\^3 copies/gm. If a participant produced multiple results for a given study day, the result with the largest shedding response was used for analysis. Samples that were reported as "Not Quantifiable" or as lower than the limit of detection (LOD) were analyzed as ½2\*LOD (76.2).

    Time frame: Pre-challenge up to Day 8 of Challenge Phase (equal to Study Day 36)

  12. Geometric Mean GCs of NoV Shedding in Emesis Measured by qRT-PCR

    NoV shedding was assessed by qRT-PCR. Emesis samples were reported in 10\^3 copies/mL. If a participant produced multiple results for a given study day, the result with the largest shedding response was used for analysis. Samples that were reported as "Not Quantifiable" or as lower than the limit of detection (LOD) were analyzed as ½2\*LOD (15.3).

    Time frame: Pre-challenge up to Day 8 of Challenge Phase (equal to Study Day 36)

  13. Duration of NoV Infection

    Duration of NoV Infection was defined as the time from NoV infection to the time of resolution of infection, defined as a negative qRT-PCR result not followed by a positive qRT-PCR result.

    Time frame: Up to approximately Day 57

Other outcomes

  1. VP1 GI.1-specific Fecal IgA at Day 1, Day 28 and Day 57

    Fecal samples for immunogenicity assessments were collected on Day 1 (prior to vaccination), Day 28 (1 day prior to challenge), and Day 57 (28 days post-challenge). VP1 GI.1-specific IgA antibody values were normalized by the total IgA in each sample.

    Time frame: Day 1 (baseline), Day 28 and Day 57

  2. VP1 GI.1-specific Saliva IgA at Day 1, Day 28 and Day 57

    Saliva samples were collected on Day 1 (prior to vaccination), Day 28 (1 day prior to challenge), and Day 57 (28 days post-challenge). VP1 GI.1-specific IgA antibody values were normalized by the total IgA in each sample.

    Time frame: Day 1 (baseline), Day 28 and Day 57

07

Results

Posted May 6, 2025

Participant flow

Participants were enrolled at 1 center in the United States (US) between December 2021 and October 2023.

Participant flow — Overall Study
MilestoneVXA-G1.1-NNPlacebo
Started8679
Entered challenge phase7665
Completed5242
Not completed3437
Withdrew: Lost to follow-up03
Withdrew: Study terminated by sponsor3027
Withdrew: Other47

Outcome measures

PrimaryNumber of Participants Who Experienced Norovirus Gastroenteritis (NVG)

NVG is a composite endpoint defined as meeting both the definition of AGE and NV. AGE was defined as meeting any one of 3 criteria (diarrhea, vomiting, or diarrhea and vomiting) in any 24-hr rolling period. The individual criteria for diarrhea, vomiting, or diarrhea and vomiting were as follows: 1\. Diarrhea: i. ≥ 3 loose or liquid stools in any 24-hr rolling period, or ii. 400 g of loose or liquid stools in any 24-hr rolling period 2. Vomiting: ≥ 2 vomiting episodes in any 24-hr rolling period, or 3. Diarrhea and vomiting: i. one vomiting episode plus any loose or liquid stool in any 24-hr rolling period ii. one vomiting episode plus ≥ 2 of the following events in any 24-hr rolling period: 1. nausea 2. fever (oral temperature ≥ 37.6°C) 3. abdominal cramps or pains 4. abdominal gurgling or bloating 5. myalgia NV infection was defined as having 1 or more positive results in stool or urine by quantitative real time reverse transcription polymerase chain reaction (qRT-PCR).

Time frame:
Up to approximately Day 57
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Norovirus Gastroenteritis (NVG)
ParticipantsVXA-G1.1-NNPlacebo
Number of Participants Who Experienced Norovirus Gastroenteritis (NVG)3437
PrimaryLevels of Viral Protein 1, Major Capsid, or Surface Protein of Viruses (VP1)-Specific Immunoglobulin A (IgA) Antibody-Secreting Cell (ASC) Against Norwalk at Day 8

Blood samples were collected at different timepoints throughout the study.

Time frame:
Day 8
Reported as:
Mean · cells/10^6 PBMCs
Levels of Viral Protein 1, Major Capsid, or Surface Protein of Viruses (VP1)-Specific Immunoglobulin A (IgA) Antibody-Secreting Cell (ASC) Against Norwalk at Day 8
cells/10^6 PBMCsVXA-G1.1-NNPlacebo
Levels of Viral Protein 1, Major Capsid, or Surface Protein of Viruses (VP1)-Specific Immunoglobulin A (IgA) Antibody-Secreting Cell (ASC) Against Norwalk at Day 879.5 (69.2 to 87.6)0 (0.0 to 4.6)
PrimaryGeometric Mean Titer (GMT) of Histo-blood Group Antigen (HBGA) Blocking Antibodies Against NV by Blocking Titer 50 (BT50) at Day 28

Blood samples were collected at different timepoints throughout the study. A positive change indicates an increase in titers.

Time frame:
Day 28
Reported as:
Geometric mean · Geometric mean titer
Geometric Mean Titer (GMT) of Histo-blood Group Antigen (HBGA) Blocking Antibodies Against NV by Blocking Titer 50 (BT50) at Day 28
Geometric mean titerVXA-G1.1-NNPlacebo
Geometric Mean Titer (GMT) of Histo-blood Group Antigen (HBGA) Blocking Antibodies Against NV by Blocking Titer 50 (BT50) at Day 28131.6 (101.2 to 171.2)33.2 (26.4 to 41.8)
PrimaryVP1-specific Serum Immunoglobulin G (IgG) Response at Day 28

Blood samples were collected at different timepoints throughout the study.

Time frame:
Day 28
Reported as:
Geometric mean · AU/mL
VP1-specific Serum Immunoglobulin G (IgG) Response at Day 28
AU/mLVXA-G1.1-NNPlacebo
VP1-specific Serum Immunoglobulin G (IgG) Response at Day 284413573.1 (3167431.7 to 6149975.6)700657.0 (508361.8 to 965690.5)
PrimaryVP1-specific Serum IgA at Day 28

Blood samples were collected at different timepoints throughout the study.

Time frame:
Day 28
Reported as:
Geometric mean · AU/mL
VP1-specific Serum IgA at Day 28
AU/mLVXA-G1.1-NNPlacebo
VP1-specific Serum IgA at Day 285555338.7 (3713874.2 to 8309863.5)670496.0 (450873.7 to 997097.1)
SecondaryNumber of Participants Who Experienced Solicited Symptoms of Reactogenicity

Solicited symptoms of reactogenicity included: * Gastrointestinal reactions: nausea, vomiting, diarrhea and abdominal pain * Systemic reactogenicity: malaise/fatigue, anorexia, fever, headache and myalgia

Time frame:
Up to Day 8
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Solicited Symptoms of Reactogenicity
ParticipantsVXA-G1.1-NNPlacebo
Number of Participants Who Experienced Solicited Symptoms of Reactogenicity5036
SecondaryNumber of Participants Who Experienced Unsolicited Adverse Events (AEs) During the Vaccination Phase

Unsolicited AEs referred to any AEs that occurred during a clinical trial but were not specifically pre-defined or actively sought by the study protocol. Unsolicited AEs could include any medical condition or symptom, whether or not it was related to the intervention being studied.

Time frame:
Up to Day 28 of Vaccination Phase (28-days phase)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Unsolicited Adverse Events (AEs) During the Vaccination Phase
ParticipantsVXA-G1.1-NNPlacebo
Number of Participants Who Experienced Unsolicited Adverse Events (AEs) During the Vaccination Phase79
SecondaryNumber of Participants Who Experienced Serious AEs (SAEs), AEs of Specific Interest (AESIs), and New Onsets of Chronic Illness (NOCIs)

A SAE was any AE that resulted in one or more of the following outcomes: death, a life-threatening event where the subject was at immediate risk of death (not hypothetically), inpatient hospitalization or the prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of normal life functions, congenital abnormality or birth defect, or an important medical event that, that jeopardized the participant's health or required medical or surgical intervention to prevent a serious outcome. A NOCI was defined as the diagnosis post-study drug administration of a new medical condition, which was chronic in nature, including those potentially controllable by medication (e.g., diabetes, asthma).

Time frame:
Up to approximately 12 months post vaccination
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Serious AEs (SAEs), AEs of Specific Interest (AESIs), and New Onsets of Chronic Illness (NOCIs)
ParticipantsVXA-G1.1-NNPlacebo
All SAEs01
All AESI01
All NOCI00
SecondaryNumber of Participants Who Experienced Unsolicited AEs During the Challenge Phase

Unsolicited AEs referred to any AEs that occurred during a clinical trial but were not specifically pre-defined or actively sought by the study protocol. Unsolicited AEs could include any medical condition or symptom, whether or not it was related to the intervention being studied.

Time frame:
Up to Day 29 of Challenge Phase (28-days phase)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Unsolicited AEs During the Challenge Phase
ParticipantsVXA-G1.1-NNPlacebo
Number of Participants Who Experienced Unsolicited AEs During the Challenge Phase3123
SecondaryNumber of Participants With AGE During the Inpatient Challenge Phase

AGE was defined as meeting any one of 3 criteria (diarrhea, vomiting, or diarrhea and vomiting) in any 24-hr rolling period. The individual criteria for diarrhea, vomiting, or diarrhea and vomiting were as follows: 1\. Diarrhea: i. ≥ 3 loose or liquid stools produced in any 24-hr rolling period, or ii. 400 g of loose or liquid stools produced in any 24-hr rolling period 2. Vomiting: ≥ 2 vomiting episodes in any 24-hr rolling period, or 3. Diarrhea and vomiting: i. one vomiting episode plus any loose or liquid stool in any 24-hr rolling period ii. one vomiting episode plus ≥ 2 of the following events in any 24-hr rolling period: 1. nausea 2. fever (oral temperature ≥ 37.6°C) 3. abdominal cramps or pains 4. abdominal gurgling or bloating 5. myalgia

Time frame:
Day 28 of Challenge Phase (28-days phase)
Reported as:
Count of participants · Participants
Number of Participants With AGE During the Inpatient Challenge Phase
ParticipantsVXA-G1.1-NNPlacebo
Number of Participants With AGE During the Inpatient Challenge Phase4039
SecondarySeverity of AGE Assessed Using the Modified Vesikari Scale

The Modified Vesikari Scale is a tool used to assess the severity of AGE by evaluating symptoms such as diarrhea, vomiting, fever, and dehydration. It scores these symptoms based on their frequency and severity, with a minimum score of 0 and a maximum score of 20, where higher scores indicate more severe symptoms and lower scores suggest milder or no symptoms and severity.

Time frame:
Up to approximately Day 36
Reported as:
Mean · Score on scale
Severity of AGE Assessed Using the Modified Vesikari Scale
Score on scaleVXA-G1.1-NNPlacebo
Severity of AGE Assessed Using the Modified Vesikari Scale4.2 (3.5 to 4.8)4.4 (3.8 to 5.1)
SecondaryNumber of Participants Who Experienced Moderate or Severe Gastroenteritis

Moderate or severe gastroenteritis was defined by cumulative loose stools ≥ 1000gr during the inpatient period.

Time frame:
Up to approximately Day 57
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Moderate or Severe Gastroenteritis
ParticipantsVXA-G1.1-NNPlacebo
Number of Participants Who Experienced Moderate or Severe Gastroenteritis147
SecondaryDuration of AGE

Time to onset of AGE was calculated as the time from challenge administration to the first recorded instance of an event satisfying the criteria for AGE. AGE was defined as meeting any of the 3 criteria: 1\. Diarrhea: i. ≥ 3 loose or liquid stools in any 24-hr rolling period, or ii. 400 g of loose or liquid stools in any 24-hr rolling period 2. Vomiting: ≥ 2 vomiting episodes in any 24-hr rolling period, or 3. Diarrhea and vomiting: i. one vomiting episode plus any loose or liquid stool in any 24-hr rolling period ii. one vomiting episode plus ≥ 2 of the following events in any 24-hr rolling period: 1. nausea 2. fever (oral temperature ≥ 37.6°C) 3. abdominal cramps or pains 4. abdominal gurgling or bloating 5. myalgia

Time frame:
Up to approximately Day 57
Reported as:
Median · Hours
Duration of AGE
HoursVXA-G1.1-NNPlacebo
Duration of AGE59.0 (26.7 to 117.3)55.8 (28.6 to 107.1)
SecondaryNumber of Participants Who Experienced Incidences of Diarrhea or Emesis

Classification of diarrhea was done through grading stools with Grade 3 (thick liquid stool) to Grade 5 (clear water diarrheal stool) being considered diarrhea.

Time frame:
Up to approximately Day 57
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Incidences of Diarrhea or Emesis
ParticipantsVXA-G1.1-NNPlacebo
Diarrhea5244
Emesis2833
SecondaryNumber of Participants With Norovirus (NoV) Infection up to Challenge Period Day 8

NoV infection was defined as a positive qRT-PCR in stool or emesis up to Challenge Period Day 8, and the presence of NV antigen in stool.

Time frame:
Challenge Phase Day 8 (equal to Study Day 36)
Reported as:
Count of participants · Participants
Number of Participants With Norovirus (NoV) Infection up to Challenge Period Day 8
ParticipantsVXA-G1.1-NNPlacebo
Number of Participants With Norovirus (NoV) Infection up to Challenge Period Day 84453
SecondaryGeometric Mean Genome Copies (GCs) of NoV Shedding in Stool Measured by qRT-PCR

NoV shedding was assessed by qRT-PCR. Stool samples were reported on 10\^3 copies/gm. If a participant produced multiple results for a given study day, the result with the largest shedding response was used for analysis. Samples that were reported as "Not Quantifiable" or as lower than the limit of detection (LOD) were analyzed as ½2\*LOD (76.2).

Time frame:
Pre-challenge up to Day 8 of Challenge Phase (equal to Study Day 36)
Reported as:
Geometric mean · 10^3 copies/gm
Geometric Mean Genome Copies (GCs) of NoV Shedding in Stool Measured by qRT-PCR
10^3 copies/gmVXA-G1.1-NNPlacebo
Pre-challenge76.2 (NA to NA)76.2 (NA to NA)
Challenge Phase Day 176.2 (NA to NA)76.2 (NA to NA)
Challenge Phase Day 2255.1 (143.9 to 452.1)341.2 (165.6 to 702.7)
Challenge Phase Day 36238.9 (2230.9 to 17447.5)15833.5 (5555.2 to 45129.2)
Challenge Phase Day 41970.7 (637.9 to 6088.1)16834.9 (4817.1 to 58834.9)
Challenge Period Day 55412.0 (1150.7 to 25454.6)31096.5 (4975.1 to 194366.0)
Challenge Phase Day 61268.7 (0.0 to 4.2004828*10^18)4483.0 (0.1 to 207897355.4)
Challenge Phase Day 8627.3 (340.0 to 1157.1)2737.3 (1400.4 to 5350.3)
SecondaryGeometric Mean GCs of NoV Shedding in Emesis Measured by qRT-PCR

NoV shedding was assessed by qRT-PCR. Emesis samples were reported in 10\^3 copies/mL. If a participant produced multiple results for a given study day, the result with the largest shedding response was used for analysis. Samples that were reported as "Not Quantifiable" or as lower than the limit of detection (LOD) were analyzed as ½2\*LOD (15.3).

Time frame:
Pre-challenge up to Day 8 of Challenge Phase (equal to Study Day 36)
Reported as:
Geometric mean · 10^3 copies/mL
Geometric Mean GCs of NoV Shedding in Emesis Measured by qRT-PCR
10^3 copies/mLVXA-G1.1-NNPlacebo
Challenge Phase Day 258.4 (19.8 to 172.4)457.3 (110.2 to 1897.5)
Challenge Phase Day 374.5 (24.9 to 222.7)152.5 (43.9 to 530.3)
Challenge Phase Day 415.3 (NA to NA)15.3 (NA to NA)
Challenge Phase Day 515.3 (NA to NA)15.3 (NA to NA)
SecondaryDuration of NoV Infection

Duration of NoV Infection was defined as the time from NoV infection to the time of resolution of infection, defined as a negative qRT-PCR result not followed by a positive qRT-PCR result.

Time frame:
Up to approximately Day 57
Reported as:
Median · Hours
Duration of NoV Infection
HoursVXA-G1.1-NNPlacebo
Duration of NoV Infection120.1 (113.4 to 126.4)115.8 (109.5 to 122.2)
Other pre-specifiedVP1 GI.1-specific Fecal IgA at Day 1, Day 28 and Day 57

Fecal samples for immunogenicity assessments were collected on Day 1 (prior to vaccination), Day 28 (1 day prior to challenge), and Day 57 (28 days post-challenge). VP1 GI.1-specific IgA antibody values were normalized by the total IgA in each sample.

Time frame:
Day 1 (baseline), Day 28 and Day 57
Reported as:
Geometric mean · μg/mg
VP1 GI.1-specific Fecal IgA at Day 1, Day 28 and Day 57
μg/mgVXA-G1.1-NNPlacebo
Day 1715.61 (442.64 to 1156.92)470.86 (316.78 to 699.89)
Day 281888.49 (1221.06 to 2920.74)444.31 (304.83 to 647.60)
Day 576122.41 (3891.96 to 9631.10)5047.07 (3000.20 to 8490.39)
Other pre-specifiedVP1 GI.1-specific Saliva IgA at Day 1, Day 28 and Day 57

Saliva samples were collected on Day 1 (prior to vaccination), Day 28 (1 day prior to challenge), and Day 57 (28 days post-challenge). VP1 GI.1-specific IgA antibody values were normalized by the total IgA in each sample.

Time frame:
Day 1 (baseline), Day 28 and Day 57
Reported as:
Geometric mean · μg/mg
VP1 GI.1-specific Saliva IgA at Day 1, Day 28 and Day 57
μg/mgVXA-G1.1-NNPlacebo
Day 10.40 (0.31 to 0.51)0.31 (0.27 to 0.35)
Day 281.15 (0.84 to 1.57)0.35 (0.31 to 0.40)
Day 571.81 (1.33 to 2.44)1.84 (1.41 to 2.40)

Adverse events

Collected over Up to approximately 16 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VXA-G1.1-NN0/86 (0%)0/86 (0%)55/86 (64%)
Placebo0/79 (0%)1/79 (1.3%)47/79 (59.5%)
Most frequent serious events
Most frequent serious events
EventVXA-G1.1-NNPlacebo
Deep vein thrombosisVascular disorders0/861/79
CellulitisInfections and infestations0/861/79
Most frequent other events
Most frequent other events
EventVXA-G1.1-NNPlacebo
HeadacheNervous system disorders34/8633/79
MalaiseGeneral disorders25/8620/79
DiarrhoeaGastrointestinal disorders20/8612/79
Abdominal painGastrointestinal disorders14/868/79
MyalgiaMusculoskeletal and connective tissue disorders11/8612/79
NauseaGastrointestinal disorders13/8610/79
Decreased appetiteMetabolism and nutrition disorders10/868/79

Baseline characteristics

Full Analysis Population (FAP): all randomized participants analyzed by randomized vaccination group assignment, who received study vaccination (active or placebo), and had available data for the specified analysis.

Age, Continuous
Age, Continuous(years)VXA-G1.1-NNPlaceboTotal
Mean36 ± 834 ± 735 ± 8
Sex: Female, Male
Sex: Female, Male(Participants)VXA-G1.1-NNPlaceboTotal
Female433174
Male434891
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)VXA-G1.1-NNPlaceboTotal
Hispanic or Latino373370
Not Hispanic or Latino494695
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)VXA-G1.1-NNPlaceboTotal
American Indian or Alaska Native101
Asian5813
Native Hawaiian or Other Pacific Islander000
Black or African American211435
White5454108
More than one race538
Unknown or Not Reported000
08

Study locations

1 site
  • AltaSciences LA
    Cypress, California 90630, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Apr 2023, 15 months.

Results were first posted in May 2025, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2022
First posted
Jan 27, 2022
StartActual
Dec 27, 2021
Primary completionActual
Apr 13, 2023
CompletionActual
Oct 27, 2023
Results first posted
May 6, 2025
Last update
Nov 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05212168
Lead sponsor
Vaxart
Responsible party
Sponsor
First posted
Jan 27, 2022
Start date
Dec 27, 2021
Primary completion
Apr 13, 2023
Completion
Oct 27, 2023
Results posted
May 6, 2025
Last update
Nov 5, 2025

Study contacts

James Cummings, MD
study director · Vaxart, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VXA-G1.1-NN

Start the discussion